Table III.

Adjusted^a and weighted^b mean proportion of cycles (95% CI) resulting in implantation, clinical pregnancy and live birth in association with urinary oxidative stress biomarkers among 478 women undergoing 992 IVF and IUI cycles.

	Implantation	p-valuec	Clinical pregnancy	p-valuec	Live birth	p-valuec
8-iso-PGF  2α
T1 lower	0.40 (0.33, 0.47)	0.49	0.36 (0.29, 0.43)	0.45	0.30 (0.24, 0.37)	0.57
T2 middle	0.44 (0.37, 0.51)		0.39 (0.33, 0.47)		0.33 (0.26, 0.40)
T3 upper	0.39 (0.32, 0.46)	0.32	0.33 (0.27, 0.40)	0.20	0.26 (0.21, 0.33)	0.17
F  2  -IsoP-M
T1 lower	0.39 (0.33, 0.46)	0.21	0.34 (0.28, 0.41)	0.04	0.27 (0.21, 0.34)	0.03
T2 middle	0.46 (0.38, 0.54)		0.44 (0.37, 0.52)		0.38 (0.31, 0.45)
T3 upper	0.36 (0.30, 0.44)	0.07	0.29 (0.23, 0.36)	P < 0.01	0.23 (0.17, 0.29)	P < 0.01

^aAdjusted for maternal age (continuous), maternal BMI (continuous), smoking (never vs. ever), primary infertility diagnosis (male, female, unexplained), race (white vs. other) and type of procedure (IVF vs. IUI).

^bModels were weighted to account for number of cycles with weights assigned using inverse number of cycles.

^c  P-value represents differences compared to the 2^nd tertile.

Note: There were 5 cycles missing information on BMI (2 women), 1 cycle missing 8-iso-PGF_2α (1 woman) and 3 cycles missing F₂-IsoP-M (3 women).

Abbreviations: 8-isoprostane-PGF_2α (8-iso-PGF_2α); 8-isoprostane-PGF_2α metabolite (F2-isoP-M); IVF and IUI.